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Abstract 
A Stability indicating Reverse-Phase liquid chromatographic method for the simultaneous estimation 
of DF and MP was developed. The chromatographic assay involves the use of Hi Q C18 W, 150 x 4.6mm, 
5µm column with a simple mobile phase composition of Acetonitrile & HPLC Grade water in the ratio of 
70:30%v/v at a flow rate of 1mL/min with U.V detection at wavelength of 220 nm. The method showed good 
linearity in the concentration range of 50-100 μg/mL for DF and 0.20-0.40 μg/mL for MP. The proposed 
method was also successfully applied to 20 tablets of marketed formulation (Arthotec). The developed method 
was successfully validated as per the ICH guidelines for following parameters. Accuracy, precision, 
repeatability, ruggedness, robustness, system suitability tests, etc. The RSD for Intra-day and Inter-day 
precision was found to be 0.96-1.85, 1.02-1.83 For DF and 0.55-0.59, 0.59-0.63 for MP. The average 
percentage recoveries for DF were found to be 90.83, 99.74, 100.21 and for MP it was found to be 100.83, 
98.94, 99.72. which was in good agreement with labeled amount of Pharmaceutical formulation. The stability 
indicating capacity was tested by accelerated degradation of marketed formulation in acidic (0.1 N HCl), basic 
(0.1 N NaOH), Neutral (water), Oxidative (3% H2O2), Thermal (60
0
C), Sunlight exposure.  
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1. Introduction 
The technique HPLC is so called because of 
its improved performance over the classical column 
chromatography. The technique basically involves the 
use of porous material as a stationary phase and the 
liquid mobile phase is pumped into the column under 
high pressure. The development of this technique is 
attributed to the small particle size of stationary 
phase. As the particle size is small the resistance to 
the flow of mobile phase is very high that is the 
reason why the high pressure is recommended.
1, 2
 The 
stability indicating assays are defined as validated 
quantitative analytical methods that can detect the 
changes with time in the chemical, physical, or 
microbiological properties of the drug substance and 
drug product, and that are specific so that the contents 
of active ingredient, degradation products, and other 
components of interest can be accurately measured 
without interference. Stress testing is the main tool 
that is use to predict stability problems, develop 
analytical methods, and identify degradation product 
and pathways. Stress testing is likely to be carried out 
on single batch of the drug substance. It should 
include the effect of temperature in 10ºC increments 
(Eg.50ºC, 60ºC etc). Above that for accelerated 
testing, humidity (Eg. 75% RH or greater) where 
appropriate oxidation and photolysis on the drug 
substance. The testing should also evaluate the 
susceptibility of the drug substance to hydrolysis 
across a wide range of pH values when in solution or 
suspension
13, 21
. Photostability testing should be an 
integral part of stress testing. The review of 
literature
9-17
 has suggested that there are few methods 
reported for estimation of selected drugs singly and in 
combination however, no stability indicating assay 
method has been reported for estimation of these 
drugs in combined dosage form. So the present work 
was undertaken with following objective to developed 
economical, simple, accurate, precise and 
reproducible stability indicating assay method for 
estimation of these drugs in combined dosage form 
with the use of different modern instruments. 
Diclofenac sodium [Figure 1] chemically is 2-(2-(2, 
6-dichlorophenylamino) phenyl) acetic acid and it is 
freely soluble in methanol and ethanol, sparingly 
soluble in water and acetic acid, practically insoluble 
in diethyl ether. It is used in Inflammatory disease 
(rheumatic arthritis, alkylosing spondylysis), Pain 
(postoperative orthopedic, gynecologic, 
Dysmenorrhoea). While misoprostol [Figure 2] 
chemically is Methyl 7-((1R, 2R, 3R)-3-hydroxy-2-
((S, E)-4-hydroxy-4-methyloct-1-enyl)-5-
oxocyclopentyl) heptanoate. And it is Soluble in 
ethanol, sparingly soluble in acetonitrile and 
practically insoluble in water. It is used in Antiulcer 
Agent, Oxytocics
18-19
.  
 
Figure 1: Chemical structure of Diclofenac sodium 
 
 
Figure 2: Chemical structure of Misoprostol 
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2. Experimentals 
2.1 Reagents and chemicals: DF supplied as a gift 
sample by Zim Labortaries Ltd, Nagpur and MP 
supplied as a gift sample by Wockheardt 
Pharamceutical Ltd, Aurangabad. All the chemicals 
used of HPLC Grade (Merk Ltd., Mumbai) and 
double distilled water was used for mobile phase 
preparation. 
2.2 Instrument: HPLC system of JASCO JASCO 
Gradient Mode HPLC JASCO PU-2080 Plus 
Intelligent HPLC Pump. JASCO PU-2075 Plus 
Intelligent HPLC Detector. with column of  Hi Q C18 
W(150 mm x 4.6mm), 5  is used. A gradient elution 
is performed using mixture of Acetonitrile & HPLC 
Grade water in the ratio of 70:30%v/v as a mobile 
phase at flow rated of 1 ml/min at detection 
wavelength of 220 nm.  
2.3 Preparation of Mobile phase: The mobile phase 
was chosen based on literature survey and several 
trials with acetonitrile and water in various 
proportions. A mobile phase consisted of acetonitrile: 
water (70:30 v/v) was selected to achieve symmetrical 
peak and sensitivity. 
2.3.1 Preparation of Stock Standard Solution 
(Solution A): Standard stock solution was prepared 
by dissolving 50.0 mg of DF and 0.2 mg of MP in 
10.0 mL was water that give concentration 1000 and 
4 μg/mL for DF and MP respectively. 
2.3.2 Preparation of Working Standard Solution 
(Solution B): From the standard stock solution, the 
mixed standard solutions were prepared    using 
acetonitrile to contain 50 µg/mL of DF and 0.2 µg/mL 
of MP. 
2.4 Selection of detection wavelength: UV detector 
was selected, as it is reliable and easy to set at 
constant wavelength. A fix concentration of analyte 
were analysed at different wavelengths. As per the 
response of analyte, 220 nm was selected. 
2.5 Linearity Study: From the standard stock 
solution of DF and MP 0.5 – 1.0 mL were taken in 10 
mL volumetric flask diluted up to the with acetonitrile 
such that final concentration of DF and MP in the 
range 50-100 µg/mL of DF and 0.2-0.4 µg/mL of MP 
respectively. Volume of 20µl of each sample was 
injected with the help of Hamilton Syringe. All 
measurements were repeated five times for each 
concentration and calibration curve was constructed 
by plotting the peak area versus the drug 
concentration. 
2.6 Analysis of Marketed Formulation: Accurately 
weighed quantity equivalent to 50.0 mg of DF and 
0.20 mg MP was transferred to 50 mL of volumetric 
flask containing water and volume was adjusted to 
mark with water, and filtered through Whatman filter 
paper. An appropriate volume, 0.5 mL was diluted to 
10 mL with acetonitrile. The resulting solution (20 µl) 
was injected into the system and chromatogram was 
recorded. The concentration was determined by using 
linear regression equation. Amount of drug estimated 
in mg/tablet and percent label claim was calculated 
using following formula: Calculate the amount of 
DF/MP in mg / tablet using following formula: 
 
                     AT1 x WS1 x Ds x P1     
Mg/tablet = ----------------------------- x  Avg.wt        
                      AS1 x WT x Dt         
                            
Where, 
AT1  =   = Average area of DF/MP peak in test 
chromatograms  
AS1 = Average area of DF/MP  peak in standard  
chromatograms 
WS1 = Weight of DF/MP working standard taken 
in mg 
 WT = Weight of sample taken in mg 
 P1 = Potency of DF/MP  working standard in % 
w/w on as such basis  
Avg.wt. 
Ds 
Dt 
= 
= 
= 
Average weight of Tablet. 
Dilution factor for standard. 
Dilution factor for test. 
Further calculate the amount of DF/MP 
present in % of Label claim using following 
formula 
                                  Assay (mg/tablet) x 100 
% Label Claim =   ------------------------------------ 
                                   Label claim of DF/MP   
2.7 Method Validation: The proposed method was 
validated as per ICH guidelines. The solutions of the 
drugs were prepared as per the earlier adopted 
procedure given in the experiment. 
2.7.1. Accuracy: It was done by recovery study using 
standard addition method at 80%, 100% and 120% 
level; known amount of DF and MP standard was 
added to preanalysed sample and subjected to the 
proposed HPLC method. The percent recovery was 
then calculated by using following formula 
                                            Ew - B                     
                 % Recovery =   ----------   X 100 
                        C                
Where, Ew   = Total drug estimated (mg) 
             B = Amount of drug contributed by   
                    preanalyzed capsule powder (mg)                                        
             C= Weight of pure drug added (mg). 
2.7.2. Precision: Precision of the method was studied 
as intra-day and inter- day variation and also 
repeatability of sample injections. Intra- day precision 
was determined by analyzing, the three different 
concentration 60 µg/mL, 80 µg/mL and 100µg/mL of 
DF and 0.24 µg/mL, 0.32 µg/mL and 0.40 µg/mL of 
MP respectively, for three times in the same day. Inter 
day variability was assessed using above mentioned 
three concentration analysed on three different days, 
over a period of one week.  
2.7.3. Repeatability: It was performed by injecting 
sample 50 µg/mL of DF and 0.2 µg/mL of MP into 
the system and measuring the peak area. It was 
repeated for six times.  
2.7.4. Ruggedness: Ruggedness of the method was 
studied by two different analyst using same 
operational and environmental condition. An 
appropriate concentration 50 µg/mL of DF and 0.2 
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µg/mL of MP was analysed and concentration were 
determined. The procedure was repeated for six times. 
2.7.5. Robustness: Robustness of the method was 
studied by making deliberate variation in parameters 
such as flow rate (± 0.1mL), % of  acetonitrile in the 
mobile phase composition (± 10%), and change in 
detection wavelength (±2 nm) and the effect on the results 
were examined. It was performed using 50 µg/mL and 0.2 
µg/mL solution of DF and MP in triplicate. 
2.7.6. System suitability test: According to USP, 
system suitability test are integral part of liquid 
chromatography methods. System suitability testing is 
essential for the assurance of the quality performance 
of the chromatographic condition were tested for 
system suitability testing. 
2.8 Forced degradation studies 
 Forced degradation carried out by applying 
various stress conditions to study the effect over wide 
range of pH, heat, and oxidation and photo 
degradation using the following approach. Stress 
studies were conducted in aqueous solutions.   
2.8.1. Acid Degradation: Accurately weight tablet 
equivalent to 50.0 mg of DF & 0.2mg of MP were 
dissolved in 5.0 mL of aqueous 0.1N hydrochloric 
acid in a separate volumetric flask and refluxed in 
round bottom flask on boiling water bath for 1 hr.   
2.8.2. Alkali Degradation: Accurately weight tablet 
equivalent to 50.0 mg of DF & 0.2mg of MP were 
dissolved in 5.0 mL of aqueous 0.1N sodium 
hydroxide in a separate volumetric flask and refluxed 
in round bottom flask on boiling water bath for 1hr. 
2.8.3. Neutral Degradation: Accurately weight 
tablet equivalent to 50.0 mg of DF & 0.2mg of MP 
were dissolved in 10.0 mL of water in a separate 
volumetric flask and kept at room temperature for 
1hr. 
2.8.4. Oxidative Degradation: Accurately weight 
tablet equivalent to 50.0 mg of DF & 0.2mg of MP 
were dissolved in 10.0 mL of 3% H2O2 in a separate 
volumetric flask and refluxed in round bottom flask 
on boiling water bath for 1hr. 
2.8.5. Thermal Degradation: Accurately weight 
tablet equivalent to 50.0 mg of DF & 0.2mg of MP 
were uniformly spread as thin layer in a separate 
covered Petri-dish which were then kept in oven at 
60°C for 24 hrs.  
2.8.6. Photo Degradation: Accurately weight tablet 
equivalent to 50.0 mg of DP & 0.2mg of MP were 
uniformly spread as thin layer in a separate covered 
Petri-dish which were then kept in sunlight for 3 days.  
 
3. Results and Discussion 
3.1HPLC Method Development and Optimization:  
  The finally optimized chromatographic 
conditions are.  
Mobile phase               Mixture of Acetonitrile & HPLC Grade 
water in the ratio of 70:30%v/v 
Column Hi Q C18 W, 150 x 4.6mm, 5µm 
Detection 220nm 
Flow rate 1.0ml/min 
Injection vol. 20µl 
Column oven temp Ambient 
 
Figure 3: Optimized chromatogram of DF and MP. 
 
 
 
2. Linearity:  
Table 1: Linearity studies of DF 
 
Concentration of 
DF [µg/mL ] 
Peak Area ± SD  (n=5) % RSD 
50 6325229 55804.33 0.88 
60 7590270 76336.61 1.02 
70 8855325 46660.01 0.52 
80 10120363 48156.14 0.47 
90 11385410 213570.03 1.87 
100 12650458 231509.12 1.83 
 
Figure 4: Linearity studies of DF. 
 
 
 
Table 2: Linearity studies of MP 
Concentration of 
MP [µg/mL ] 
Peak Area 
± SD 
(n=5) 
% RSD 
0.20 354975 6704.38 1.88 
0.24 399970 2194.38 0.55 
0.28 454965 2599.80 0.57 
0.32 519963 2670.91 0.52 
0.36 581875 2965.73 0.50 
0.40 650120 3509.13 0.59 
 
Figure 5: Linearity studies of MP 
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3.2 Analysis of Marketed formulation:  
Table 3: results of marketed formulation analysis 
Brand Name: Arthotec                                                                                      Avg. Wt: 2034 mg 
 
3.3 Method Validation
6
:  
3.3.1. Accuracy: It was ascertained by recovery 
studies based on standard addition method at level of 
80%, 100%, 120%.  The average percentage 
recoveries for DF was found to be 90.83, 99.74, 
100.21 and for MP it was found to be 100.83, 98.94, 
99.72. which was in good agreement with labeled 
amount of Pharmaceutical formulation. 
Table 4: Recovery studies of DF 
Label 
claim 
(mg/Tab) 
Amount 
Added 
(mg) 
Total 
Amount 
Amount 
Recovered 
(mg) 
% 
RSD 
% 
Recovery 
50 40 (80%) 90 89.78 0.96 90.83 
50 50(100%) 100 99.74 0.14 99.74 
50 60(120%) 110 107.26 0.88 100.21 
 
Table 5: Recovery studies of MP 
Label 
claim 
(mg/Tab) 
Amount 
Added( 
mg) 
Total 
Amount 
Amount 
Recovered 
(mg) 
% 
RSD 
% 
Recovery 
0.2 0.16 (80%) 0.36 0.363 0.89 100.83 
0.2 0.20 
(100%) 
0.40 0.390 0.12 98.94 
0.2 0.24 
(120%) 
0.44 0.437 0.92 99.72 
 
3.3.2. Precision:  
 Precision of the method was studied as intra-day and 
inter- day variation and also repeatability of sample  
injections. Intra- day precision was determined by 
analyzing, the three different concentration 60 µg/mL, 
80 µg/mL and 100µg/mL of DF and 0.24 µg/mL, 0.32 
µg/mL and 0.40 µg/mL of MP respectively, for three 
times in the same day. Inter day variability was 
assessed using above mentioned three concentration 
analysed on three different days, over a period of one 
week. 
 
Table 6: Precision studies on DF 
 
 
Table 7: Precision studies on MP 
 
Conc. 
[µg/mL
] 
Intra-day Amount found 
[µg/mL] 
Inter-day Amount found 
[µg/mL] 
Mean ±SD n=3 % 
RSD 
Mean ±SD n=3 % 
RSD 
0.24 0.241 2144.38 0.55 0.236 2294.38 0.59 
0.32 0.325 2670.91 0.52 0.331 2610.73 0.48 
0.40 0.412 3509.13 0.59 0.409 3459.13 0.63 
3.3.3 Repeatability: 
Table 8: Repeatability studies on DF and MP 
Concentration of 
DF [µg/mL] 
Peak 
Area 
Concentration of 
MP [µg/mL] 
Peak 
Area 
50 6325229 0.20 351870 
50 6339270 0.20 351201 
50 6314059 0.20 351269 
50 6295780 0.20 351109 
Mean 6314018  351362 
± SD 18371.75  820.79 
%RSD 0.29  0.20 
  
3.3.4. Ruggedness: Ruggedness of the method was 
studied by two different analyst using same 
operational and environmental condition. An 
appropriate concentration 50 µg/mL of DF and 0.2 
µg/mL of MP was analysed and concentration were 
determined. 
Table 9: Ruggedness studies on DF 
Condition Mean ± SD n=3 %RSD 
Analyst I 6325229 38371.75 0.59 
Analyst II 6339270 40715.50 0.64 
 
Table 10: Ruggedness studies on MP 
Condition Mean ± SD n=3 %RSD 
Analyst I 350132 1210.05 0.34 
Analyst II 347690 1597.98 0.45 
 
3.3.5. Robustness:   
Table 11: Robustness studies on DF 
Condition Mean ± SD n=3 %RSD 
Change in flow rate 
(± 0.1 ml) 
6286519 36492.14 0.58 
Change in detection 
wavelength (± 2 nm) 
6289541 35715.50 0.60 
 
Table 12: Robustness studies on Mp 
Condition Mean ± SD  n=3 %RSD 
Change in flow rate (± 
0.1 ml) 
342890 1574.49 0.35 
Change in detection 
wavelength (± 2 nm) 
349803 2598.56 0.57 
 
3.3.6. System suitability test:  
Table 13: System suitability studies for DF and MP. 
System 
Suitability 
Parameter 
Standard Proposed 
Method of 
MP 
Proposed 
Method of 
DF 
Retention time (tR) 
[min] 
5-10 min 2.3 4.8 
Resolution Should be 
> 2 
- 2.98 
Theoretical plate 
(N) 
More than 
2000 
2078 3510 
Sr. 
No. 
Weight of 
std.(mg) 
Weight of 
sample 
Peak area of std Peak area of sample % Label claim 
DF MP (mg) DF MP DF MP DF MP 
1. 
50 0.2 
2034 
6325229 354975 
6314028 351870 99.82 99.12 
2. 2032 6305156 351269 99.68 98.95 
3. 2036 6312439 351109 99.72 98.89 
Mean 99.74 98.94 
±S.D. n=3 0.1475 0.1193 
%RSD 0.14 0.12 
Conc. 
[µg/mL] 
Intra-day Amount found 
[µg/mL] 
Inter-day Amount found 
[µg/mL] 
Mean ±SD  n=3 % 
RSD 
Mean ±SD  n=3 % 
RSD 
60 59.72 76336.61 1.02 58.91 74229.31 0.96 
80 78.90 48156.14 0.47 79.43 49170 0.48 
100 98.54 231509.12 1.83 99.20 241609.12 1.85 
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Force degradation studies
4
:  
Table 14: Summary of force degradation studies. 
Condition 
%Assay 
DF 
% 
Degradation 
DF 
%Assay 
MP 
% 
Degradation 
MP 
Initial sample 99.74 - 98.95 - 
0.1N  HCL 97.24 2.53 98.50 - 
0.1N NaOH 97.74 - 98.50 0.45 
3% H2O2 98.44 1.30 97.90 1.05 
Thermal 98.96 0.78 97.37 0.89 
Neutral 99.72 - - - 
Sun 96.45 3.29 98.50 0.45 
 
Figure 6: Chromatogram of acid degradation 
 
Figure 7: Chromatogram of Alkali degradation 
 
Figure 8: Chromatogram of Neutral degradation 
 
 
Figure 9: Chromatogram of oxidative 
degradation
 
Figure 10: Chromatogram of sunlight degradation 
 
 
Figure 11: Chromatogram of thermal degradation  
 
 
 The parent drug peak was well resolved from 
all the degradants generated under various stress 
conditions. However it could not be ascertain that 
peaks of degradants with similar retention times under 
different stress condition were same chemical entity 
or different. In this regard further studied may be 
pursued in order to isolate and characterize 
degradants of different stress conditions. The DF was 
susceptible to acid, photolytic, thermal and oxidative 
degradation and MP was susceptible to alkali, 
oxidative, thermal and photolytic degradation in the 
marketed formulation. 
 
4. Conclusion  
The proposed method was validated as Per 
the ICH Guidelines. The proposed method also 
showed the good resolution between DF and MP with 
run time of 15 min. The method is very simple and 
rapid and no where involves complicated sample 
preparation and mobile phase preparation. Also the 
proposed method showed good specificity and 
selectivity in order to determine DF and MP in the 
presence of their degradation products. The linearity 
and reproducibility data of the drugs carried out by 
this method showed that no major interference is 
caused in the estimation of the drugs. Therefore the 
method can be use for routine quality control of these 
drugs.  
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